/startuppedia/media/media_files/2026/01/09/copy-of-website-1110-x-960-px-28-2026-01-09-17-56-15.png)
Deepinder Goyal Defends Temple
For some time now, Deepinder Goyal and his venture Eternal, have been in the public eye, initially over debates surrounding gig-economy working conditions linked to Zomato, Blinkit and now for an entirely different reason.
The Backlash
The latest discussion is around a wearable brain-health device called Temple, which Deepinder Goyal was seen wearing during a recent appearance on the Raj Shamani Podcast.
The device, a small sensor placed near the temple, claims to continuously monitor cerebral blood flow.
While Temple has not been commercially launched, its visibility sparked immediate criticism from sections of the medical community, particularly neuroscientists and clinicians who questioned both its scientific grounding and the optics of publicly wearing an unvalidated health device.
Criticism from doctors
Among the most pointed critics was Dr. Suvrankar Datta, a radiologist at AIIMS Delhi and an early researcher in arterial stiffness.
Posting on X, Dr. Datta described Temple as a “fancy toy for billionaires” with “zero scientific standing” as a medical instrument. He cautioned consumers against spending money on unproven technology, stating that measurements taken from temporal arteries cannot substitute for established diagnostic tools.
The criticism was also echoed and highlighted by Dr. Rahul Chawla, a neurologist trained at AIIMS, New Delhi, consultant neurologist at IBS Hospital, Lajpat Nagar, and founder of HealthPil.com.
Commenting on the device, he said: “The obsession with 'longevity' is making billionaires do ridiculous experiments and wear fancy 'devices' in public. If you really want to spend on research, there are people who aredoing exemplary work, support them. But the priority here looks to sell devices based on futile research.”
Deepinder Goyal responds on LinkedIn
As the debate gained momentum online, Deepinder Goyal responded through a LinkedIn post, pushing back against what he viewed as premature criticism.
He pointed out that Temple has:
neither been commercially announced
nor released,
and that scientific work and validation are still underway.
He noted that“you’re advising people not to buy an ‘unvalidated’ device” that is not even available yet, while adding that skepticism is welcome, but at the right time.”

